Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene

Eli Lilly and Company10 个研究点分布在 1 个国家目标入组 200 人开始时间: 2004年11月最近更新: 2007年5月25日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方: Eli Lilly and Company
入组人数: 200
试验地点: 10
主要终点: Change in calcium values after beginning teriparatide

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 50 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•Postmenopausal women aged at least 50 years
•A previous clinical diagnosis of osteoporosis
•At high risk for fracture
•Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na

排除标准

•History of metabolic bone disease other than osteoporosis
•History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma

结局指标

主要结局

Change in calcium values after beginning teriparatide

次要结局

Frequency of hypercalcemia, various calcium assessments, change in bone mineral density and tests of bone formation and resorption

研究者

发起方

Eli Lilly and Company

申办方类型

Industry

研究点 (10)

Loading locations...

相似试验

进行中（未招募）

1 期

Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action. A two year open label single arm study of teriparatide in secondary care. - Teriparatide Treatment in Postmenopausal Women: Mechanism of ActioMedDRA version: 12.1 Level: LLT Classification code 10031282 Term: OsteoporosisOsteoporosis

EUCTR2010-021009-19-GBSheffield Teaching Hospitals NHS Foundation Trust20

已完成

3 期

Comparison Medications in the Treatment of Postmenopausal Women With OsteoporosisOsteoporosis, Postmenopausal

NCT00542984Eli Lilly and Company70

已完成

3 期

PTH Comparison in Post Menopausal WomenOsteoporosis, Post-Menopausal

NCT00543218Eli Lilly and Company63

已完成

3 期

A Study of the Treatment of Postmenopausal Women With OsteoporosisOsteoporosis, Post-Menopausal

NCT00543023Eli Lilly and Company104

已完成

3 期

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With OsteoporosisOsteoporosis, Postmenopausal

NCT00046137Eli Lilly and Company